Raven is RA Capital’s healthcare incubator.From discovery to delivery, whether we incubate, accelerate or rejuvenate, Raven’s goal is to turn scientific breakthroughs into transformative therapies and get them quickly, safely and efficiently to the patients that need them most.Raven seeks to build companies that make life better, and that our healthier, more productive future demands.

Precision targeted biologics for oncology and immunologyIncubated by RA Capital's Raven Incubator

Next-gen gene writing companyIncubated by RA Capital's Raven Incubator

Rationally-designed molecular glues for oncologyIncubated by RA Capital's Raven Incubator

Next-generation small molecule drugs for CF patientsIncubated by RA Capital's Raven Incubator

Acquired by Abbvie Dec 2024Next-gen blood brain barrier technology. Clinical lead program in Alzheimer's Disease. Incubated by RA Capital's Raven Incubator.

Acquired by Novartis, 2024Best-in-class radiopharamceutical company with broad oncology pipelineIncubated by RA Capital's Raven Incubator

Acquired by Merck, 2023Mitophagy and selective autophagy for neurodegenerative diseases. Aquired by Merck

MRL Ventures is Merck's biotherapeutics venture fund

Acquired by Coherus, 2023. Next-generation immuno-oncology Ab therapeutics

Acquired by Novartis, 2020Small molecule therapeutics for neuromotor and neuropsych diseases

Acquired by Novartis, 2014Immuno-oncology platform. Pipline included PD1, first-in-class TIM3, first-in-class LAG3

Led Investments in infectious disease and biodefense for venture arm of American Society for Microbiology

Early web-based expert system diagnostic engine for patients